BR112019023592A8 - Formas cristalinas de seletalisibe - Google Patents
Formas cristalinas de seletalisibeInfo
- Publication number
- BR112019023592A8 BR112019023592A8 BR112019023592A BR112019023592A BR112019023592A8 BR 112019023592 A8 BR112019023592 A8 BR 112019023592A8 BR 112019023592 A BR112019023592 A BR 112019023592A BR 112019023592 A BR112019023592 A BR 112019023592A BR 112019023592 A8 BR112019023592 A8 BR 112019023592A8
- Authority
- BR
- Brazil
- Prior art keywords
- seletalisib
- crystalline forms
- oncological
- nociceptive
- neurodegenerative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
As formas cristalinas de seletalisibe, designadas como Forma B e Forma F, e aqui caracterizadas, são inibidores seletivos das enzimas PI3 quinase, em particular da isoforma PI3Kd humana, são adequadamente benéficas na medicina, por exemplo, no tratamento de doenças inflamatórias, autoimunes, cardiovasculares, neurodegenerativas, metabólicas, oncológicas, nociceptivas ou oftálmicas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1708856.8 | 2017-06-02 | ||
GBGB1708856.8A GB201708856D0 (en) | 2017-06-02 | 2017-06-02 | Seletalisib crystalline forms |
PCT/EP2018/063640 WO2018219772A1 (en) | 2017-06-02 | 2018-05-24 | Crystalline forms of seletalisib |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112019023592A2 BR112019023592A2 (pt) | 2020-05-26 |
BR112019023592A8 true BR112019023592A8 (pt) | 2023-05-09 |
Family
ID=59349914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019023592A BR112019023592A8 (pt) | 2017-06-02 | 2018-05-24 | Formas cristalinas de seletalisibe |
Country Status (17)
Country | Link |
---|---|
US (1) | US11059820B2 (pt) |
EP (1) | EP3630760A1 (pt) |
JP (1) | JP7264829B2 (pt) |
KR (1) | KR102591329B1 (pt) |
CN (2) | CN114573580A (pt) |
AR (1) | AR112062A1 (pt) |
AU (1) | AU2018276243B2 (pt) |
BR (1) | BR112019023592A8 (pt) |
CA (1) | CA3062533A1 (pt) |
CL (1) | CL2019003510A1 (pt) |
CO (1) | CO2019014026A2 (pt) |
EA (1) | EA201992839A1 (pt) |
GB (1) | GB201708856D0 (pt) |
IL (1) | IL270937A (pt) |
MX (1) | MX2019013518A (pt) |
RU (1) | RU2019143761A (pt) |
WO (1) | WO2018219772A1 (pt) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
GB0428475D0 (en) * | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
MD20160137A2 (ro) * | 2014-05-27 | 2017-05-31 | Almirall S.A. | Utilizare medicală |
GB201506786D0 (en) | 2015-04-21 | 2015-06-03 | Ucb Biopharma Sprl | Therapeutic use |
GB201608797D0 (en) | 2016-05-19 | 2016-07-06 | Ucb Biopharma Sprl | Therapeutic use |
-
2017
- 2017-06-02 GB GBGB1708856.8A patent/GB201708856D0/en not_active Ceased
-
2018
- 2018-05-24 JP JP2019566167A patent/JP7264829B2/ja active Active
- 2018-05-24 KR KR1020197037460A patent/KR102591329B1/ko active IP Right Grant
- 2018-05-24 US US16/615,992 patent/US11059820B2/en active Active
- 2018-05-24 BR BR112019023592A patent/BR112019023592A8/pt unknown
- 2018-05-24 RU RU2019143761A patent/RU2019143761A/ru unknown
- 2018-05-24 CA CA3062533A patent/CA3062533A1/en active Pending
- 2018-05-24 MX MX2019013518A patent/MX2019013518A/es unknown
- 2018-05-24 EA EA201992839A patent/EA201992839A1/ru unknown
- 2018-05-24 CN CN202210296993.6A patent/CN114573580A/zh active Pending
- 2018-05-24 EP EP18728337.9A patent/EP3630760A1/en active Pending
- 2018-05-24 CN CN201880036440.9A patent/CN110709399A/zh active Pending
- 2018-05-24 AU AU2018276243A patent/AU2018276243B2/en active Active
- 2018-05-24 WO PCT/EP2018/063640 patent/WO2018219772A1/en active Application Filing
- 2018-06-01 AR ARP180101467A patent/AR112062A1/es unknown
-
2019
- 2019-11-26 IL IL270937A patent/IL270937A/en unknown
- 2019-11-29 CL CL2019003510A patent/CL2019003510A1/es unknown
- 2019-12-12 CO CONC2019/0014026A patent/CO2019014026A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR112062A1 (es) | 2019-09-18 |
US11059820B2 (en) | 2021-07-13 |
EA201992839A1 (ru) | 2020-04-08 |
CA3062533A1 (en) | 2018-12-06 |
AU2018276243A1 (en) | 2019-12-19 |
BR112019023592A2 (pt) | 2020-05-26 |
CO2019014026A2 (es) | 2020-01-17 |
CL2019003510A1 (es) | 2020-04-17 |
US20200095246A1 (en) | 2020-03-26 |
CN110709399A (zh) | 2020-01-17 |
AU2018276243B2 (en) | 2021-11-25 |
IL270937A (en) | 2020-01-30 |
JP2020521793A (ja) | 2020-07-27 |
MX2019013518A (es) | 2020-02-10 |
CN114573580A (zh) | 2022-06-03 |
RU2019143761A (ru) | 2021-07-09 |
GB201708856D0 (en) | 2017-07-19 |
KR20200012902A (ko) | 2020-02-05 |
JP7264829B2 (ja) | 2023-04-25 |
WO2018219772A1 (en) | 2018-12-06 |
EP3630760A1 (en) | 2020-04-08 |
KR102591329B1 (ko) | 2023-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20190558A (es) | Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos | |
BR112016029630A2 (pt) | derivados heteroaromáticos bicíclicos fundidos como inibidores de inibidores de cinase | |
CR20170167A (es) | Derivados de imidazol pentacíclicos fusionados | |
BR112016011792A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
BR112018008017A2 (pt) | composição farmacêutica, método de preparação de composição farmacêutica líquida, kit farmacêutico, sistema de fornecimento de injeção | |
BR112016012990A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
BR112016016916A2 (pt) | método de tratamento de angiodema hereditário (hae) | |
MX2019015311A (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
MX2023008211A (es) | Composiciones y metodos para disminuir la expresion de tau. | |
BR112013004750A2 (pt) | derivados de quinolina e quinoxalina como inibidores da cinase | |
EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
BR112016012258A2 (pt) | Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf | |
MX2017007852A (es) | Formulaciones de acido hipocloroso y metodos para tratar afecciones de la piel. | |
MA52542A (fr) | Thérapie cellulaire adoptive | |
CL2015002620A1 (es) | Derivados piridin-4-ilo | |
BR112016029632A2 (pt) | derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase | |
DK3464550T3 (da) | Beholdere og spinnerkobler med reduceret hjulslør til dyrkning af celler | |
BR112016029558A2 (pt) | terapia de células-tronco em patologias endometriais | |
BR112017001971A2 (pt) | ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais? | |
BR112016029635A2 (pt) | derivados pirazolo-piridina como inibidores de quinase | |
EP3880151A4 (en) | DETERMINATION OF THE TREATMENT RESPONSE IN SINGLE CELLS | |
BR112018012913A2 (pt) | tratamento in situ de sementes em sulco | |
GB201805287D0 (en) | Haematoietic stem cell treatment | |
PL3589298T3 (pl) | Mezenchymalne komórki macierzyste pochodzące z galarety whartona do leczenia sepsy | |
BR112019023592A8 (pt) | Formas cristalinas de seletalisibe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: UCB BIOPHARMA SRL (BE) |